Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
Ratings
Vertex Pharmaceuticals: Strong Prescription Growth and Strategic Initiatives Bolster Buy Rating
8d ago
VRTX
Premium
Ratings
Vertex Pharmaceuticals: Promising Growth with Successful Launch and Strong Pipeline
15d ago
VRTX
Premium
The Fly
Vertex Pharmaceuticals downgraded to Neutral from Buy at DA Davidson
26d ago
VRTX
Premium
Ratings
Vertex Pharmaceuticals: Hold Rating Amid Mixed Q2 Results and Pain Management Setbacks
27d ago
VRTX
Premium
Ratings
Vertex Pharmaceuticals: Strong Commercial Performance and Promising Future Prospects Support Buy Rating
27d ago
VRTX
Premium
Ratings
Vertex Pharmaceuticals: Hold Rating Amid Growth Concerns and Market Challenges
27d ago
VRTX
Premium
Ratings
Vertex Pharmaceuticals: Buy Rating Upgraded to Overweight Amid Promising Pipeline and Strong Financial Position
27d ago
VRTX
Premium
The Fly
Disney reports Q3 beat and NFL deal, Uber authorizes $20B buyback: Morning Buzz
27d ago
U
GO
Premium
The Fly
Snap downgraded, Leidos upgraded: Wall Street’s top analyst calls
27d ago
IT
ALC
Premium
The Fly
Vertex Pharmaceuticals price target lowered to $411 from $424 at Canaccord
27d ago
VRTX
Premium
The Fly
Vertex Pharmaceuticals upgraded to Overweight from Equal Weight at Wells Fargo
27d ago
VRTX
Premium
Company Announcements
Vertex Pharmaceuticals: Strong Growth and Strategic Advances
27d ago
VRTX
Premium
The Fly
Video: Palantir, Axon lead early movers after earnings
28d ago
IT
TDG
Premium
The Fly
video: Why These Stocks Are Moving Today
28d ago
IT
TDG
Premium
The Fly
Vertex Pharmaceuticals price target lowered to $490 from $520 at Truist
28d ago
VRTX
Premium
The Fly
Vertex Pharmaceuticals price target lowered to $455 from $494 at Stifel
28d ago
VRTX
Premium
The Fly
Vertex Pharmaceuticals price target lowered to $553 from $582 at UBS
28d ago
VRTX
Premium
The Fly
Vertex Pharmaceuticals price target lowered to $530 from $557 at BMO Capital
28d ago
VRTX
Premium
The Fly
Vertex price target lowered to $478 from $550 at H.C. Wainwright
28d ago
VRTX
Premium
The Fly
Vertex Pharmaceuticals price target lowered to $439 from $460 at Morgan Stanley
28d ago
VRTX
Premium
Ratings
Vertex Pharmaceuticals: Strong Financials Overshadowed by Challenges in Pain Program Leading to Hold Rating
28d ago
VRTX
Premium
Ratings
Vertex Pharmaceuticals: Strong Financial Performance and Promising Pipeline Justify Buy Rating
28d ago
VRTX
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >
You need to enable JavaScript to run this app.
